2584 related articles for article (PubMed ID: 18609187)
21. Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis.
Lindström L; Lapidus A; Ost A; Bergquist A
Dis Colon Rectum; 2011 Nov; 54(11):1392-7. PubMed ID: 21979184
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory bowel disease in Iran: a review of 457 cases.
Aghazadeh R; Zali MR; Bahari A; Amin K; Ghahghaie F; Firouzi F
J Gastroenterol Hepatol; 2005 Nov; 20(11):1691-5. PubMed ID: 16246187
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological study of colorectal cancer occurring in patients with ulcerative colitis: results from a single hospital in Japan.
Fujita T; Ando T; Watanabe O; Hasegawa M; Miyake N; Kondo S; Kato T; Ishiguro K; Nakamura M; Miyahara R; Ohmiya N; Niwa Y; Goto H
Hepatogastroenterology; 2010; 57(99-100):487-92. PubMed ID: 20698214
[TBL] [Abstract][Full Text] [Related]
24. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
25. Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis.
Braden B; Halliday J; Aryasingha S; Sharifi Y; Checchin D; Warren BF; Kitiyakara T; Travis SP; Chapman RW
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):303-8. PubMed ID: 22037429
[TBL] [Abstract][Full Text] [Related]
26. Review article: colorectal carcinoma and inflammatory bowel disease.
Eaden J
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():24-30. PubMed ID: 15352890
[TBL] [Abstract][Full Text] [Related]
27. Dysplasia and cancer in inflammatory bowel disease.
Basseri RJ; Basseri B; Papadakis KA
Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):59-66. PubMed ID: 21309672
[TBL] [Abstract][Full Text] [Related]
28. High lifetime risk of cancer in primary sclerosing cholangitis.
Claessen MM; Vleggaar FP; Tytgat KM; Siersema PD; van Buuren HR
J Hepatol; 2009 Jan; 50(1):158-64. PubMed ID: 19012991
[TBL] [Abstract][Full Text] [Related]
29. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?
Burgmann T; Clara I; Graff L; Walker J; Lix L; Rawsthorne P; McPhail C; Rogala L; Miller N; Bernstein CN
Clin Gastroenterol Hepatol; 2006 May; 4(5):614-20. PubMed ID: 16630762
[TBL] [Abstract][Full Text] [Related]
30. Are patients with inflammatory bowel disease receiving optimal care?
Reddy SI; Friedman S; Telford JJ; Strate L; Ookubo R; Banks PA
Am J Gastroenterol; 2005 Jun; 100(6):1357-61. PubMed ID: 15929770
[TBL] [Abstract][Full Text] [Related]
31. Relationship of inflammatory bowel disease and primary sclerosing cholangitis.
Fausa O; Schrumpf E; Elgjo K
Semin Liver Dis; 1991 Feb; 11(1):31-9. PubMed ID: 2047887
[TBL] [Abstract][Full Text] [Related]
32. Increased risk for demyelinating diseases in patients with inflammatory bowel disease.
Gupta G; Gelfand JM; Lewis JD
Gastroenterology; 2005 Sep; 129(3):819-26. PubMed ID: 16143121
[TBL] [Abstract][Full Text] [Related]
33. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease.
Torres J; Pineton de Chambrun G; Itzkowitz S; Sachar DB; Colombel JF
Aliment Pharmacol Ther; 2011 Sep; 34(5):497-508. PubMed ID: 21692821
[TBL] [Abstract][Full Text] [Related]
34. [Inflammatory bowel disease and colorectal cancer].
Hagymási K; Tulassay Z
Orv Hetil; 2006 Oct; 147(41):1977-82. PubMed ID: 17120688
[TBL] [Abstract][Full Text] [Related]
35. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database.
Vind I; Riis L; Jess T; Knudsen E; Pedersen N; Elkjaer M; Bak Andersen I; Wewer V; Nørregaard P; Moesgaard F; Bendtsen F; Munkholm P;
Am J Gastroenterol; 2006 Jun; 101(6):1274-82. PubMed ID: 16771949
[TBL] [Abstract][Full Text] [Related]
36. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
Sjöqvist U; Tribukait B; Ost A; Einarsson C; Oxelmark L; Löfberg R
Anticancer Res; 2004; 24(5B):3121-7. PubMed ID: 15510599
[TBL] [Abstract][Full Text] [Related]
37. Chemoprevention for colon cancer: new opportunities, fact or fiction?
Terhaar Sive Droste JS; Tuynman JB; Van Dullemen HM; Mulder CJ
Scand J Gastroenterol Suppl; 2006; (243):158-64. PubMed ID: 16782636
[TBL] [Abstract][Full Text] [Related]
38. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis.
D'Haens GR; Lashner BA; Hanauer SB
Am J Gastroenterol; 1993 Aug; 88(8):1174-8. PubMed ID: 8338083
[TBL] [Abstract][Full Text] [Related]
39. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
Bernstein CN; Blanchard JF; Metge C; Yogendran M
Am J Gastroenterol; 2003 Dec; 98(12):2784-8. PubMed ID: 14687833
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis.
Karlsen TH; Hampe J; Wiencke K; Schrumpf E; Thorsby E; Lie BA; Broomé U; Schreiber S; Boberg KM
Am J Gastroenterol; 2007 Jan; 102(1):115-21. PubMed ID: 17100974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
